Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease

J. ten Berg*, D. Sibbing, B. Rocca, E. Van Belle, B. Chevalier, J.P. Collet, D. Dudek, M. Gilard, D.A. Gorog, J. Grapsa, E.L. Grove, P. Lancellotti, A.S. Petronio, A. Rubboli, L. Torracca, G. Vilahur, A. Witkowski, J. Mehilli

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

67 Citations (Web of Science)


Transcatheter aortic valve implantation (TAVI) is effective in older patients with symptomatic severe aortic stenosis, while the indication has recently broadened to younger patients at lower risk. Although thromboembolic and bleeding complications after TAVI have decreased over time, such adverse events are still common. The recommendations of the latest 2017 ESC/EACTS Guidelines for the management of valvular heart disease on antithrombotic therapy in patients undergoing TAVI are mostly based on expert opinion. Based on recent studies and randomized controlled trials, this viewpoint document provides updated therapeutic insights in antithrombotic treatment during and after TAVI.[GRAPHICS].
Original languageEnglish
Pages (from-to)2265-2269
Number of pages5
JournalEuropean Heart Journal
Issue number23
Publication statusPublished - 14 Jun 2021


  • Transcatheter aortic valve implantation
  • Antithrombotic treatment

Cite this